Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, gel-e’s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
Location: United States, Maryland, Riverdale Park
Employees: 11-50
Total raised: $29.8M
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | Robin Hood... | robinhoodv... |
| - | TEDCO | tedcomd.co... |
| - | Aubrey Cap... | aubreycapi... |
| - | MIT Alumni... | mitalumnia... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.04.2024 | - | $22.4M | - |
| 12.08.2021 | Series A | $7.4M | - |
Mentions in press and media 13
| Date | Title | Description |
| 06.04.2024 | Medcura Secures $22.4 Million to Revolutionize Surgical Hemostasis | Medcura, a trailblazer in surgical hemostasis, has locked in a hefty $22.4 million in convertible debt to propel the development of its groundbreaking LifeGel™ Absorbable Hemostatic Gel. Led by CEO Jim Buck and Executive Chair Larry Tiffany... |
| 03.04.2024 | Medcura Closes $22.4M in Convertible Debt | Medcura, a Riverdale, MD-based developer of hemostatic products for use in surgery, closed a $22.4m in in convertible debt. Backers were not disclosed. The company intends to use the funds to accelerate the development of its lead surgical ... |
| 03.04.2024 | Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio | RIVERDALE, Md., April 3, 2024 /PRNewswire/ -- Medcura, Inc., a developer of hemostatic products for use in surgery, today announced that it has closed a private placement with aggregate gross proceeds of US $22.4 million (the "Offering... |
| 02.05.2022 | Power Moves: University of Maryland, Baltimore appoints new medical dean | Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, gig or promotion? Email us: baltimore@technical.ly.UMB has a new dean of medicine Dr. Mark T. Gladwin has been named the new dean of ... |
| 19.08.2021 | UMD spinout Medcura raises $7.4M Series A for products that stop bleeding, treat wounds | Medcura, a Riverdale-based medical device company, recently closed on $7.4 million in a Series A financing round that will help advance its products, which are designed to stop bleeding and treat wounds. Based out of a facility in the Unive... |
| 16.08.2021 | Maryland’s Medcura raises $7.4M Series A for products that stop bleeding, treat wounds | Medcura, a Riverdale-based medical device company, recently closed on $7.4 million in a Series A financing round that will help advance its products, which are designed to stop bleeding and treat wounds. Based out of a facility in the Unive... |
| 12.08.2021 | Medcura raises $7.4 Million to Expand FDA-Approved Line of Hemostatic and Wound Treatment Products | RIVERDALE, Md., Aug. 12, 2021 /PRNewswire/ -- Medcura, Inc., a commercial-stage medical device company, today announced it has raised $7.4 million in private equity to support its growing product line and development of its lead surgical ca... |
| 12.08.2021 | Medcura raises $7.4 Million to Expand FDA-Approved Line of Hemostatic and Wound Treatment Products | |
| 12.08.2021 | Medcura Raises $7.4M in Funding | Medcura, Inc., a Riverdale, Md.-based commercial-stage medical device company, raised $7.4m in funding. The financing includes the sale of Series A Preferred stock as well as common stock based, in part, from certain investors benefitting f... |
| 12.07.2021 | Medcura Launches a New Class of High-Performance, Antibacterial Hemostats | RIVERDALE, Md., July 12, 2021 /PRNewswire/ -- Medcura, Inc., a commercial-stage medical device company, in partnership with ASO, LLC, a major U.S. manufacturer and supplier of first aid products, announced today the launch of a high-perform... |
Show more